The effect of empagliflozin on diuresis and neurohumoral factors in the patients with decompensated heart failure and diabetes mellitus: pilot study

The effect of empagliflozin on diuresis and neurohumoral factors in the patients with decompensated heart failure and diabetes mellitus: pilot study - EmpaHF-P

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027431

Enrollment

Registered

2017-05-21

Start date

2017-05-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

decompensated heaat failure type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The hospitalized decomposed heart failure patients with type 2 diabetes mellitus 2. The type 2 diabetes mellitus patient who is planned empagliflozin administration for poorly controlled hyperglycemia by attending physician 3. Patient who is obtained informed consent

Exclusion criteria

Exclusion criteria: 1. Patient who has contraindication for empagliflozin administration 2. Patient who is in shock at registeration 3. Patient who is undergone or required intra-aortic balloon pumping (IABP), percutaneous cardiopulmonary support (PCPS) and/or dialysis at registration 4. Patient who cannot be obtained informed consent 5. Patient who is judged as unsuitable for this study by attending physician

Design outcomes

Primary

Measure	Time frame
Urine output during a day	—

Secondary

Measure	Time frame
amount of furosemide injection intravenously Holter electrocardiography Echocardiography neurohumoral factors	—

Countries

Japan

Contacts

Public ContactYoichi Ajiro

National Hospital Organization Yokohama Medical Center Department of Cardiology

you617bacchus@gmail.com045-851-2621

Outcome results